Adverse Events Associated With Outcomes in PD-1/PD-L1–Treated Urothelial Carcinoma
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.
Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.